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Abstract
To evaluate the medication safety of chemotherapy drugs at a tertiary care 
hospital, with complete reporting of prescription errors, classifying prescription 
errors, complete detailing of watched medication administration errors (MAEs) 
by nurses, ordering watched MAEs, and figuring improvement methodologies. 
Likewise, in relation to side effects, how to overcome side effects, which antiemetic 
treatments to use, how to survey the appropriateness of requesting and apportion-
ing. An imminent, observational, non-interventional contemplate study was driven 
at the Oncology Department, Baptist Hospital, Bangalore for half a year. All the 
data was collected from patient medical records according to case record structure. 
An aggregate of 70 patients tolerating chemotherapy were observed for information 
on a sort of side effects, prescription missteps and other relevant information like 
demographic findings, treatments, and drugs used to manage the adverse effects 
(AEs) collected from the patient’s medical records. The data was characterized 
reliant on various parameters. The watched side effects according to different 
organ frameworks were orchestrated and appeared differently in relation to the 
distributed writing and bundle embeds. Among the 70 patients, 22 (31.4%) were 
males and 48 (68.57%) were females. Moreover, the age interval within these two 
groups was of 20–65. From the 70 patients, the number of chemotherapy cycles was 
of one for 14 (20%) patients, two for 16 (22.85%), three for 16 (22.85%), four for 
5 (7.14%), five for 6 (8.57%), six for 9 (12.85%), and more than six for 4 (5.71%) 
patients, mostly due to maintenance chemotherapy. The evaluation of our informa-
tion uncovered that the cancer with the most elevated predominance was breast 
cancer (24.28%), pursued by blood and bone marrow cancer (5.71%) in females, 
whereas in males were blood and bone marrow (4.28%), followed by lung cancer 
(2.85%), non-Hodgkin lymphoma (2.85%), and colon cancer (2.85%). The present 
study demonstrated that in both gender groups, the most influenced organ frame-
work was gastro intestinal tract (GIT), trailed by skin and subcutaneous tissue, 
musculoskeletal, blood and nervous system. The most prescribed antiemetic drug 
was ondansetron (81.42%), and the normally endorsed chemotherapy agents in our 
setting were shown to be cisplatin (21.42%), carboplatin (17.14%), and paclitaxel 
(14.28%). The total percentage of errors on the 70 prescriptions was 24.28. Most 
of the errors were due to drug–drug interactions (10%). The total percentage of 
errors in drug administration performed by nurses was found to be 11.42%, out of 
which in 2.85% of the cases, it was used the wrong drug dose. The adverse impacts 
related with the usage of anticancer medication were surveyed for half a year. The 
AEs most commonly experienced suggest that for all intents and purposes, all the 
patients accepting cytotoxic drugs suffered at least one AE. The critical announced 
MAE rates on our hospital ward (0.04% of medication administration and 0.03% 
MAE/patient admission) send out an impression of being generally low due to the 
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utilization of current security rules. Emphasize on deep understanding of MAE at 
individual foundations, is likely going to result in important procedure changes, 
improved effectiveness of MAE detailing, and various focal points.
Keywords: medication safety, chemotherapy drugs, adverse effects, side effects, error 
in prescription, error in administration, emetogenic chemotherapy, antiemetic drugs, 
and comparison of antiemetic guidelines
1. Introduction
Medication safety has been recognized to be important in the provision of 
patient care for a long time. With the evidence pointing to medication errors (MEs) 
as one of the leading causes of avoidable complications and deaths, there is a press-
ing need for a better understanding of the nature and scope of MEs, and the will to 
improve the current clinical delivery systems. [1]
The chemotherapeutic agents are associated with severe adverse effects (AEs), 
leading to economic burden and decreased quality of life. [2]
The issue of medication safety in chemotherapy drugs is highly significant when 
anticancer therapy is used as a treatment modality due to the high hazards derived 
from these agents and the disease context in which they are used. [2]
The purpose of this chapter is to determine the error rate in prescribing, 
dispensing and administration of chemotherapy drugs and related agents used 
in the treatment of cancer, and to promote the prevention of MEs to improve 
patient safety.
The complexity of treatment regimens designed to achieve the maximal anti- 
cancer effect balanced against acceptable toxicity leaves limited margin for error. 
Overdosing can result in death due to treatment associated AEs, while under dosing 
can have significant implications for the management of the disease and to the 
patient outcome. [3]
MEs can occur for a number of reasons. Errors can occur when human and 
system factors interact with the complex process of prescribing, dispensing and 
administration drugs, to produce an unintended and potentially harmful outcome.
With an extreme move in the comprehension of medical errors through the 
production of the 1999 Institute of Medicine (IOM) report, To Err is Human, [4], 
the IOM board required a change in the manner health-care experts comprehend 
therapeutic error by standards ranging from subjective psychology to human fac-
tors, and investigation of human execution in workplaces.
The enhancements in aeronautics and other security-arranged businesses, for 
instance, chemical engineering, manufacturing, and nuclear power, showed that 
complex systems, instead of individual specialists, were the fundamental well-
springs of error and thus an objective for improvement openings through modifi-
cations, systematization, and innovation. Sentinel events in oncology, including 
the death of Betsy Lehman in 1994 at Boston’s Dana-Farber Cancer Institute, 
conspicuously highlighted the open impression of medicinal error. Past research has 
seemed certain patients are at an extended danger of preventable damage, which is 
associated with their restricted Physiological Reserve, (physiological reserve is the 
capacity of an organ or body part to fulfill its physiological activity), which typi-
cally joins patients with intense ailments, comorbidities, different prescriptions, 
and harmful sickness. [5, 6]
Chemotherapeutic prescriptions have a constrained therapeutic index and the 
dosage expected to give an effective response is conventionally poisonous to 
the body’s quickly multiplying cells. The typical tissues antagonistically affected by 
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the chemotherapy drugs are those, which are rapidly partitioning, like bone mar-
row, gastrointestinal tract and hair follicles. Chemotherapy drugs also have other 
organ explicit toxicities. Moreover, a couple of drugs that are usually associated 
with speedy adverse reactions are a consequence of their biochemical nature, rather 
than their activity against tumors. The use of some cancer chemotherapy drugs have 
been associated with a few AEs, usually going from mild nausea to fatal myelosup-
pression. [7]
During the most recent decade, various examinations have shown that medi-
cation inducing morbidity and mortality is one of the most significant general 
medical issues. [8]
Clinicians should be aware that chemotherapy induced nausea and vomiting 
(CINV) is one of the most complicated side effects of chemotherapy. With the 
correct use of antiemetics, CINV can be prevented in almost 70% up to 80% of the 
patients. [9]
The goal of each antiemetic treatment is to abrogate nausea and vomiting. 
Twenty years back, nausea and vomiting were typical AEs resulting from specific 
sorts of chemotherapy and which obliged up to 20% of the patients to postpone or 
decay possibly corrective treatments [10]. Clinical and major research over the span 
of ongoing years has provoked persistent enhancements in the control of CINV. [11]
The improvement of the serotonin receptor antagonists (5-HT3RAs) in the mid-
1990s was a standout among the most imperative advances in the chemotherapy of 
cancer patients. [12, 13] Another group of antiemetics discovered, the neurokinin1-
receptor antagonist (NK1RA), and the essential medication in this class, aprepitant, 
were consolidated into the refreshed antiemetic rules. [14, 15]
In 1998, the main Multinational Association of Supportive Care in Cancer 
(MASCC) antiemetic rules reliant on the outcomes of the Perugia understanding, 
were brought together and were distributed worldwide, trailed by the American 
Society of Clinical Oncology (ASCO) rules in 1999 [16]. The two guidelines, simi-
larly as the National Comprehensive Cancer Network (NCCN) rules, invigorated 
[17, 18]. The audit of antiemetics, contrasts these three rules, regarding the utiliza-
tion of antiemetics in chemotherapy settings.
2. Medication error rate
The ME rate was dictated by ascertaining the level of errors. The numerators 
in the proportion, is the absolute number of error. The numerator in the proportion 
is the complete number of error that they watch, the denominator is called “oppor-
tunities for errors” and incorporates every single watched dosage that is controlled, 
in addition to the portions requested but not directed. [19, 20]
 Number of errors observedMedication error rate 100*Opportunities for errors
=  (1)
Endorsing error happens at the time a prescriber orders a medication for a 
particular patient. The error might be due to dosage form, number of dosages, 
dose structure, course of association, and length of treatment. The MEs, includ-
ing cancer chemotherapeutic administrators, may be particularly unsafe as these 
drugs have a limited helpful profile for which prescriptions have a confined 
association that may result in expanded toxicity and/or decreased tumor response. 
Furthermore, antineoplastic administrators are consistently coordinated to be 
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applied to more established patients with comorbidities and it is novel and complex 
treatment for nurses and medication assistants. Along these lines, antineoplastic 
masters are among the most outstanding reasons of ME. [1, 19, 20]
3. Theoretical framework
According to a study on MEs on a Community Hospital Oncology Ward, it was 
found that out of 141 medication administration errors (MAEs) detected amid 
the study period, the most persistent ones were administration errors, 41%, while 
38% were either nurse or pharmacy dispensing errors, and 21% constituted order 
writing and transcribing errors. Out of these MAEs, only three errors resulted from 
adverse drug events. [20]
In another study based on the AEs.of.anticancer.drugs.in.an Oncology Centre 
of a Tertiary Care Hospital, from a total of 130 evaluated cases, 60 cases comprised 
males (46.2%), and 70 comprised females (53.8%). The most prevalent cancers 
among females were breast cancer and cervical cancer, whereas lung cancer and 
urinary bladder cancer were the most common among males. Nausea (48.5%), 
decreased appetite (39.2%), alopecia (37.7%), anemia (35.4%), vomiting (31.5%), 
and nail discoloration (30%) were the most frequently reported AEs. The com-
monly used pre medication were ondansetron, dexamethasone, aprepitant and 
proton pump inhibitors, individually or in combination. [21]
Moreover, a study regarding side effects of chemotherapy among cancer patients 
revealed that out of 99 patients, the majority had their age between 45–64 years 
(73.3%) and were females (93.3%). Nausea and vomiting were two of the most com-
mon side effects (83.3% and 78.9% respectively) reported.
Other common side effects were hair loss and loss of appetite. Also 6.7% of 
patients experienced peripheral neuropathy symptoms. [22]
3.1 Chemotherapy-induced emesis
With respect to the emetogenicity potential, the chemotherapy agents can be 
classified into four emetic risk groups: [23].
High (≥90% of patients experienced nausea and vomiting when no prophylactic 
antiemetic protection was provided);
Moderate (30–90% of patients experienced nausea and vomiting when no 
prophylactic antiemetic protection was provided);
Low (10–30% of patients experienced nausea and vomiting when no prophylac-
tic antiemetic protection was provided);
Minimal (≤10% of patients, experienced nausea and vomiting when no prophy-
lactic antiemetic protection was provided), as suggested by all three guidelines. [17, 
18, 23, 24]. Hence, antiemetic prophylaxis is directly proportional to the emetogenic 
potential of the chemotherapy.
The emetogenic potential of the drugs is different in each guideline. In the 
MASCC guideline in particular, the emetogenic potential of oral chemotherapeutic 
agents is different from intravenous chemotherapeutic agents. In MASCC and 
NCCN guidelines, intravenous etoposide is labeled as having low emetogenic poten-
tial. However, oral etoposide is usually classified as having moderate emetogenic 
potential, implying that there is a 30%–90% incidence of emesis [24].
In a recently published study by Einhorn et al, [25] oral etoposide indeed seemed 
to have only low emetogenic potential. Additionally, althought imatinib is classified 
by the MASCC and NCCN guidelines as a moderate emetogenic agent, the daily use 
of antiemetics is not recommended in the special case of imatinib by the NCCN.
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The ASCO guidelines do not implicate any of the oral chemotherapeutic agents 
in their classification system [23].
3.2 Patient-related risk factors inducing emesis
Patient-related risk factors, including age (young age usually experience more 
nausea and vomiting), gender (females generally experience more nausea and 
vomiting compared to males), a history of alcohol intake, a history of an emesis 
experience amid pregnancy, impaired quality of life, and also a history of previous 
chemotherapy, are known to increase the risk for CINV. [23, 26, 27]
3.3 Antiemetic agents
3.3.1 5-hydroxytryptamine receptor antagonists (5-HT3RAs)
These are the most effective antiemetic agents in the prophylaxis of acute 
CINV. [28]
The different 5-HT3RAs, namely dolasetron, granisetron, ondansetron, palo-
nosetron and, tropisetron appear to be interchangeable. The lowest fully effective 
single dose for each agent should be use. The oral and intravenous routes are 
similarly effective. These statements are supported by all three guidelines. [29]
1. Dolasetron: All three guidelines recommend the same doses of dolasetron, 
which are 100 mg or 1.8 mg/kg intravenously, and 100 mg orally. [29]
2. Granisetron: All three guidelines recommend granisetron at a dose of 1 mg 
or 0.01 mg/kg intravenously, and 2 mg orally (MASCC and ASCO) or 1–2 mg 
orally (NCCN). [29, 30]
3. Ondansetron: with respect to the dosing of ondansetron, different state-
ments are given. For example, the NCCN guidelines recommend ondansetron 
at a dose of 16–24 mg orally and 8–12 mg (maximum, 32 mg) intravenously, 
whereas the MASCC and ASCO guidelines recommend ondansetron at a dose 
of 24 mg orally (MASCC, 16 mg orally for moderately emetogenic chemo-
therapy) and 8 mg or 0.15 mg/kg I.V. In a recently published meta-analysis 
comparing low-dose ondansetron (8 mg) with high-dose ondansetron (24 or 
32 mg), in a sub analysis in cisplatin based chemotherapy, high-dose ondanse-
tron appeared to be more effective [29].
4. Palonosetron: All three guidelines recommend palonosetron at a dose of 0.25 mg 
intravenously. Oral palonosetron is not yet available. Palonosetron has a sig-
nificantly longer half-life and a higher binding activity compared to the other 
5-HT3RA. The actual role of palonosetron in comparison with the other available 
5-HT3RA has been controversially discussed in the guidelines. However, none 
of the three guidelines designates a preferred 5-HT3RA, although palonosetron 
outperformed ondansetron and dolasetron in some secondary endpoints in one 
reported study. [29, 31]. For a better understanding, the results of the three avail-
able randomized studies with palonosetron in the acute phase are outlined, where 
it was found that palnosetron’s effect was significantly superior to ondansetron. 
[29, 31, 32].
5. Tropisetron: An orally or intravenously dose of 5 mg is recommended for 
tropisetron according to the ASCO and MASCC guidelines. [29]
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3.3.2 Steroids
Steroids are commonly used in the treatment of several cancers, such as lymphoma 
and leukemia as they help to destroy cancer cells and render chemotherapy more 
effective reduce allergy reaction to certain drugs, and also protect the patient from 
having nausea and vomiting after a round of chemotherapy. Steroids used in chemo-
therapy include prednisolone, methyl prednisolone, and dexamethasone. [33, 34]
Dexamethasone: Although not approved as an antiemetic, dexamethasone 
plays a major role in the prevention of acute and delayed CINV and is an integral 
component of almost all antiemetic regimens [33, 34].All three guidelines recom-
mend the use of dexamethasone for the acute prevention of highly, moderately, and 
low emetogenic chemotherapy.
According to the three guidelines, for the prevention of delayed emesis, dexameth-
asone is recommended in combination with aprepitant for highly emetogenic chemo-
therapy (MASCC, ASCO, NCCN), but not for moderately emetogenic chemotherapy 
(MASCC, ASCO). Only the NCCN guidelines suggest dexamethasone as a possible 
combination partner for aprepitant with moderately emetogenic chemotherapy.
This recommendation of the MASCC and ASCO expert panel is mostly drive 
by the study of Warr et al. [35] in patients receiving moderately emetogenic che-
motherapy. In this study, aprepitant is given as monotherapy for the prevention of 
delayed CINV, and a complete response rate of 55%, in comparison with 49% for 
ondansetron, was achieved in the delayed phase.
This result might suggest that the combination of dexamethasone and aprepi-
tant in the delayed phase would have greater antiemetic efficacy. Thus this might 
be the reason why the NCCN panel was recommending this combination in the 
moderately emetogenic setting in the delayed phase.
Further studies are warranted to clarify this clinically important question. When 
combined with aprepitant, dose reduction of dexamethasone (dexamethasone 
is a sensitive substrate of the cytochrome P450 [CYP450] 3A4 enzyme) has to be 
undertaken. For the prevention of acute CINV, the dose of choice should be 20 mg 
of dexamethasone (12 mg when co administered with aprepitant). For highly 
emetogenic chemotherapy a single dose of 8 mg dexamethasone (12 mg in the 
NCCN guidelines) is enough. For moderately emetogenic chemotherapy, these 
dose recommendations were largely driven by studies from the Italian Group for 
Antiemetic Research. [36, 37].
3.3.3 Neurokinin 1 receptor antagonists (NK1RAs)
NK1 receptor antagonists are in a class of drugs used to treat nausea and vomit-
ing associated with chemotherapy. Aprepitant, casopitant, fosaprepitant, and 
rolapitant are some examples of NK1 drugs.
Aprepitant: Is the first representative of this new group that blocks the NK1 
receptor in the brainstem emetic center and gastrointestinal tract [38]. So far, it is 
only available for oral use and should be administered as 125 mg on day one, and 
80 mg on day two and day three as recommended by all three guidelines. Published 
studies have shown that the addition of NK1RAs to standard antiemetic therapy 
(5HT3RA plus dexamethasone) appears to have a significant effect in controlling 
cisplatin-induced acute as well as delayed emesis.
In all studies the aprepitant regimen was more pronounced in the delayed phase 
of CINV [38–40]. The use of aprepitant is suggested for both highly and moderately 
emetogenic chemotherapy by all three guidelines.
In the moderately emetogenic setting, one study has been published and, 
formed the basis for the recommendation of aprepitant for anthracycline and 
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cyclophosphamide– based emetogenic chemotherapy. In this study [35], the triple 
combination of ondansetron, dexamethasone, and aprepitant used in the first 
24 hours, followed by aprepitant monotherapy for another 2 days, proved to be 
superior to the whole 5-day study period (51% vs 42%). However, no significant 
differences were observed in the delayed period (49% vs 55%), possibly because only 
patients receiving an anthracycline and cyclophosphamide– based regimen were 
included in this study.
The MASCC and ASCO guidelines restricted the recommendation of the triple 
combination in the moderately emetogenic setting due to this “high-risk” chemo-
therapeutic regimen.
The NCCN guidelines, however, recommended aprepitant in the moderately emeto-
genic setting in selected patients based on the emetogenic potential of the chemotherapy.
In the MASCC guidelines, it was noted that no trials have compared so far, the combi-
nation of aprepitant with dexamethasone for delayed emesis with the previous standard 
of dexamethasone combined with a 5-HT3RA in highly emetogenic chemotherapy. [16] 
In the meantime, a study addressing this question [40] showed that the effect obtained 
from the combination of aprepitant with dexamethasone was superior to one resulting 
from the combination of ondansetron and dexamethasone in the delayed phase.
Aprepitant is a moderate inhibitor of CYP3A4; therefore, the dexamethasone 
dose has to be reduced, as discussed before. Theoretical concerns that aprepitant 
might interact with chemotherapeutic agents could not be demonstrated in preclini-
cal and clinical studies so far [16, 40, 41].
3.3.4 Metoclopramide
Metoclopramide was part of the former MASCC, ASCO, and NCCN guidelines and 
was suggested for the prevention of delayed emesis [16, 20]. Although metoclopramide 
has proved to be as effective as 5-HT3RA when combined with steroids in the preven-
tion of delayed CINV [42, 43] it is not recommended in the new guidelines in this 
setting. However, because 5-HT3RAs are recommended as an alternative to dexameth-
asone in the delayed phase for moderately emetogenic chemotherapy, metoclopramide 
might also be an adequate alternative, although not recommended by the guidelines.
3.3.5 Cannabinoids
The MASCC guidelines state that cannabinoids can be considered for refrac-
tory nausea and vomiting and as a rescue antiemetic. However, due to the weak 
antiemetic efficacy with potentially high side effects including, sedation, euphoria, 
dysphoria, dizziness, and hallucination, cannabinoids are not recommended as 
first-line treatment for the prevention of CINV.
In the ASCO and NCCN guidelines, cannabinoids are advised in patients intoler-
ant or refractory to 5-HT3RAs or steroids and aprepitant.
Interestingly, a systematic review addressing the efficacy of oral cannabinoids 
in the prevention of nausea and vomiting revealed, that cannabinoids were slightly 
more efficient than conventional anti emetics (e.g., metoclopramide, phenothi-
azines, haloperidol.). However, their usefulness was generally limited by the high 
incidence of toxic effects, such as dizziness, dysphoria, and  hallucinations. [44–46]
3.3.6 Benzodiazepines
Benzodiazepines can be useful in controlling anxiety and reduction of anticipa-
tory CINV or in patients with refractory and breakthrough emesis, as suggested by 
all three guidelines. [47]
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3.3.7 Antihistamines
The most common antihistamines used are diphenhydramine and hydroxyzine. 
Nevertheless, the available studies have not shown any significant antiemetic activ-
ity in these agents. [48]
3.3.8 Olanzapine
Olanzapine is an atypical antipsychotic drug with, antiemetic potential due 
to its action at multiple receptor sites implicated in the control of nausea and 
vomiting. [49] In a phase II trial where olanzapine was used in combination with 
granisetron and dexamethasone for the prevention of CINV, the combination 
therapy proved to be highly effective in controlling acute and delayed CINV in 
patients receiving highly and moderately emetogenic chemotherapy. [50] The 
latest phase II study published by Navari et al. [51] showed exceptionally high 
complete protection rates from both acute and delayed CINV when using a 
combination of palonosetron (day 1), dexamethasone (day 1), and olanzapine 
(days 1–4) in patients receiving highly or moderately emetogenic chemotherapy. 
Consequently, olanzapine is mentioned by the MASCC and NCCN guidelines for 
the treatment of refractory and breakthrough emesis with a suggested dose of 
2.5–5 mg.
3.4 Classification of CINV based on the guidelines
According to the guidelines CINV can be differentiated into five  categories: [52].
1. When nausea and vomiting occur within 24 hours of initial administration of 
chemotherapy is known as acute onset, which is mostly due to serotonin- re-
lated agents.
2. When nausea and vomiting occur 24 hours to several days after initial treat-
ment is known as delayed onset, which is due to substance P-related agents.
3. Anticipatory nausea and vomiting is observed in patients whose emetic epi-
sodes were triggered by taste, odor sight, thoughts, anxiety, or had a history of 
poor response to antiemetic agents or received inadequate antiemetic prophy-
laxis in the previous cycle of chemotherapy.
4. Breakthrough CINV is defined as vomiting and/or nausea that occur within 
five days of chemotherapy administration after the use of guideline directed 
prophylactic antiemetic agents. This type of CINV usually requires immediate 
treatment or requires “rescue” with additional antiemetics.
5. Refractory CINV is defined as vomiting and/or nausea occurring after chemo-
therapy, usually in subsequent chemotherapy cycles after guideline directed 
prophylactic antiemetic agents have failed in earlier cycles.
3.5 Prevention of CINV
3.5.1  Regimens linked to a high incidence of nausea and vomiting are referred as 
highly emetogenic chemotherapy (≥90%)
Acute CINV: All three guidelines suggest the combination of a 5-HT3RA, 
dexamethasone, and aprepitant within the first 24 hours of chemotherapy.
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Delayed CINV: All three guidelines suggest the combination of dexamethasone 
and aprepitant for delayed CINV. Trials have indicated that from 60% to nearly 
90% of patients receiving cisplatin will experience delayed emesis if not given 
preventive anti emetics. Therefore, appropriate prophylaxis is necessary [17, 52, 53].
3.5.2  Regimens linked to a moderate incidence of nausea and vomiting are referred 
as moderately emetogenic chemotherapy (30–90%)
Acute CINV: All three guidelines recommend the combination of a 5-HT3RA 
plus dexamethasone with or without aprepitant for acute CINV. However, the 
key question in this setting is whether aprepitant should be part of the antiemetic 
prophylaxis or not. The ASCO and MASCC guidelines recommend the triple 
combination (a 5HT3RA, dexamethasone, and aprepitant) for patients receiving the 
combination of an anthracycline and cyclophosphamide–based regimen. The NCCN 
guidelines, however, broadened the spectrum of the use and suggest using the triple 
combination in patients receiving other chemotherapy agents of moderately emeto-
genic risk like carboplatin, epirubicin, ifosfamide, or irinotecan [17, 52, 53].
Delayed CINV: Dexamethasone is the preferred agent to be used for delayed 
CINV. Nonetheless, when aprepitant is used for the prevention of acute CINV then it 
should also be used for the prophylaxis of delayed CINV as mono therapy, as stated 
by the MASCC and ASCO guidelines. As discussed before, the NCCN guidelines 
suggest aprepitant with or without dexamethasone in this situation. A 5-HT3RA 
can be used as an alternative, although their therapeutic role in the delayed phase is 
rather limited [34]. In contrast to all three previously published guidelines, metoclo-
pramide is not reflected in the new guidelines as an alternative option [17, 52, 53].
3.5.3  Regimens linked to a low incidence of nausea and vomiting are referred as 
low emetogenic chemotherapy (10–30%)
The MASCC and ASCO guidelines in unison recommend the use of a steroid 
alone in the first 24 hours and no prophylaxis beyond 24 hours for acute CINV. 
The NCCN guidelines recommend prochlorperazine or metoclopramide as well, as 
alternative drugs to dexamethasone [17, 52, 53].
3.5.4  Regimens linked to a minimal incidence of nausea and vomiting are referred 
to as minimally emetogenic chemotherapy (≤10%)
All three guidelines suggest that, for patients treated with agents of low emetic 
risk, no antiemetic drugs should be routinely administered before chemotherapy 
[17, 52, 53].
3.5.5  Regimens linked to an incidence of nausea and vomiting in case of 
anticipatory, breakthrough or refractory chemotherapy
Anticipatory, breakthrough and refractory CINV:
Anticipatory CINV is mostly seen in patients with anxiety or patients who did 
not receive adequate antiemetic prophylaxis in the previous cycle [17, 52, 53].
Breakthrough CINV is defined as an event that happens in spite of optimal 
preventive treatment.
Refractory CINV is nausea and vomiting that recurs in subsequent cycles of 
therapy when all previous preventive and rescue treatments fail.
If optimal treatment has been given as prophylaxis, repeated dosing of the same 
agents is unlikely to be successful; the addition of dopamine-receptor antagonists 
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(for instance, metoclopramide) might be useful, or the addition of other agents 
such as benzodiazepines or neuroleptics. Olanzapine, an atypical neuroleptic, could 
also be considered, as suggested by the MASCC and NCCN guidelines. [16]
3.5.6  Regimens, linked to CINV in case of receiving chemotherapy more than one 
day in a cycle
Multiple-Day chemotherapy: for patients receiving multiple day chemotherapy 
like, for instance with cisplatin, the MASCC guidelines recommend the use of a 
5-HT3RA in combination with dexamethasone for acute CINV and dexamethasone 
alone for delayed CINV. The use of NK1RAs remains to be defined, as stated by the 
MASCC guidelines. However, the NCCN guidelines advise the application of apre-
pitant for at least the first 3 days, in analogy to highly emetogenic chemotherapy. 
Furthermore, the NCCN guidelines clearly mention the use of palonosetron in this 
setting [17, 52, 53].
4. MEs involving antineoplastic agents
MEs involving cancer chemotherapy agents may be particularly harmful as these 
drugs have a narrow therapeutic index for which incorrect dosing or administration 
may result in increased toxicity and/or decreased tumor response. In addition, anti-
neoplastic agents are often administered to older patients with comorbidities and 
may be part of novel and complex treatment protocols less familiar to nurses and 
pharmacists. As a result, antineoplastic agents are among the most common causes 
of ME-related deaths. These concerns have led to an update of national guidelines, 
including recommendations for a systems approach consisting of multidisciplinary 
monitoring of medication use, prescribing guidelines, preparation and dispensing 
methods, and medication administration. [54]
5. Materials and methods
An imminent, observational, non-interventional study was led at the Oncology 
Department, Baptist Hospital, Bangalore for half a year. All patient related- data 
was gathered according to case record structure. During a 6 months period, I 
directed an imminent report on the Oncology Ward in a Tertiary Care Hospital, 
with the  following objectives:
• Complete reporting of prescription errors
• Classify prescription errors
• Complete revealing of MAEs errors detected by nurses
• Classify watched MAEs, and
• Formulate improvement procedures.
• Monitor and register the occurrence of side effects
• Assess how to overcome side effects?
• Evaluate the antiemetic treatments used,
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A survey review of a self-assertively picked test of 70 chemotherapy solicitations 
to assess the appropriateness of mentioning and administering was conducted. An 
aggregate of 70 patients getting chemotherapy met for information on sort of side 
effects, MEs and other pertinent relevant information like, diagnosis, treatment, 
drugs utilized, and arrangement with the AEs were assembled from the patient’s 
medical records. The data was arranged reliant on various parameters.
The MAEs are described as a preventable oversight in medicine association 
due to error beginning in requesting, apportioning, or overseeing. It includes 
association of (1) wrong prescription, (2) wrong dose, (3) wrong route, (4) wrong 
time, (5) a medication to which the patient has a known sensitivity, as well as, (6) 
a prescription with multiple drugs cooperation with another prescription. The 
patients accepting investigation included patients with affirmed malignancies who 
confessed that go chemotherapy in oncology wards.
As we expect to survey the resulting side effects a 6 month examination period 
was arranged. The number of patients getting chemotherapy in oncology ward for a 
half-year time span were utilized to appraise the sample measure.
6. Results and discussion
6.1 Demographic details
Age and sex:
Among the 70 patients, 22(31.4%) were males and 48(68.57%) were females. A 
further order dependent on the age uncovered that in the majority of the patients, 
both males and females were in the age range of 20–65 years. (Table 1).
Number of chemotherapy cycles:
Among the 70 patients, 14(20%) had only one chemotherapy cycle. 
16(22.85%) had two chemotherapy cycles, 16(22.85%) had three chemo-
therapy cycles, 5(7.14%) had four chemotherapy cycles, 6(8.57%) had five 
 chemotherapy cycles, 9(12.85%) had six chemotherapy cycles and, 4(5.71%) had 
more than six cycles of chemotherapy, mostly due to maintenance chemotherapy.
6.2 Chemotherapy agents
The most common endorsed chemotherapy agents in our setting.were.cisplatin 
(21.42%), carboplatin (17.14%), paclitaxel (14.28%), oxaliplatin.(12.85%), doxo-
rubicin.(11.42%), and docetaxel.(11.42%), as it can be observed in Table 2 and 
Figure 1.
6.3 Clinical diagnosis of the patients
The sub-classification based on the gender, revealed that breast (24.28%), blood and 
bone marrow (5.71%), cervical (2.85%), ovarian (2.85%), lung (2.85), non-Hodgkin 
lymphoma (2.85%), colon (2.85%), stomach (2.85%), and esophageal (2.85%) cancers 
Age group (years) Number of patients % of patients
Pediatric (0–20) 5 7.14
20–65 58 82.85
Geriatric (< 65) 7 10
Table 1. 
Cancer patient’s distribution according to the age groups.
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were the most prevalent types of cancer in females. On the other hand, blood and bone 





























Chemotherapy agents used in the setting.
Figure 1. 
Prevalence of the chemotherapy agents used in the setting according to number of prescriptions.
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marrow (4.28%), lung (2.85%), non-Hodgkin lymphoma (2.85%), colon (2.85%), and 
oral (2.85%) cancers were the most prevalent in males as it can be seen in Table 3.
Furthermore, the most common type of cancer in the age group of 0–20 years 
was blood and bone marrow cancer (4.28%), while within the age group 
20–65 years was breast cancer (24.28%) in females and oral cancer (2.85%) in 
males. In addition, in adults over 65 years breast cancer (2.85%) was the most 
prevalent in females. While in men there was not any significant type, as the occur-
rence of all the cancer types were shown to be equal. (Figure 2).
6.4 Side effects
According to Table 4, the most influenced organ framework in both females and 
males was gastro intestinal tract (GIT), trailed by skin and subcutaneous tissue, mus-
culoskeletal, blood, and nervous systems. Most of the patients have suffered the side 
effects related to GIT, such as nausea, vomiting, diarrhea and decreased appetite. The 




% of female 
patients
% of male 
patients
anorectal 0 1 0 1.42
brain 1 0 1.42 0
breast 17 0 24.28 0
blood and bone 
marrow
4 3 5.71 4.28
bone 0 1 0 1.42
cervical 2 0 2.85 0
colon 2 2 2.85 2.85
esophageal 2 0 2.85 0
head and neck 1 1 1.42 1.42
Hodgkin lymphoma 1 1 1.42 1.42
larynx 0 1 0 1.42
lung 2 2 2.85 2.85
lupus 1 0 1.42 0
neck 1 0 1.42 0
non Hodgkin 
lymphoma
2 2 2.85 2.85
oral 1 2 1.42 2.85
ovarian 2 0 2.85 0
peritoneal 1 0 1.42 0
testicular 0 1 0 1.42
thyroid 0 1 0 1.42
tongue 0 1 0 1.42
tonsil 1 1 1.42 1.42
uterus 1 0 1.42 0
rectal 0 1 0 1.42
skin 0 1 0 1.42
muscle 1 0 1.42 0
soft tissue 1 1 1.42 1.42
stomach 2 0 2.85 0
Table 3. 
Cancer prevalence among the study patients.
New Insights into the Future of Pharmacoepidemiology and Drug Safety
14
Figure 2. 
Cancer prevalence among the study patients according to gender.




ALLERGIC REACTIONS Anaphylaxis 4 5.71








ASTHENIA (weakness) AND 
CHRONIC PAIN
Fatigue 2 2.85
Feeling weak or tired 19 27.14
Fibromyalgia (pain all over
the body)
43 61.42
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GIT DISORDERS Abdominal pain 17 24.28
Constipation 17 24.28




HEART AND BLOOD VESSELS 
DISORDERS
Chest pain 1 1.42
Low blood pressure 16 22.85
HORMONAL DIORDERS Missed menstrual period 3 4.28
INFECTIONS Anal ulceration 1 1.42
Chills 6 8.57
Fever 7 10
Sore eye 1 1.42
Sore mouth 15 21.42








Loss of taste 12 17.14
MUSCULO SKELETAL &
CONNECTIVE TISSUE DISORDERS
Joint pain 17 24.28







PULMONARY DISORDERS Respiratory distress 4 5.71
RENAL &URINARY
DISORDERS
Bladder irritation 2 2.85
Blood in urine 7 10
SKIN & SUBCUTANEOUS TISSUE 
DISORDERS
Alopecia (hair loss) 25 35.71
Bruising 18 25.71
Change in skin color 3 4.28
Nail discoloration 15 21.42
Sweating 1 1.42
Table 4. 
Side-effects prevalence and distribution depending on the organ system.
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majority of the patients experienced pain all over the body, especially in the muscle 
and joints and most of the patients experienced alopecia (temporary hair loss).
There are many side effects resulting from the use of chemotherapeutic agents, and 
rapidly developing cells have been shown to be highly affected by these agents. Hair fol-
licles, skin, and the cells that line the GIT are some examples of the fastest growing cells 
in the human body, and therefore are more sensitive to the effects of chemotherapy. For 
this reason patients may experience hair loss, rashes, and diarrhea, respectively.
6.5 Antiemetics
6.5.1 Antiemetic therapy
Our analysis showed that all of the patients have used anti emetics in their 
treatment. The antiemetic used, was either a single anti emetic or a combination 
of antiemetics. Ondansetron was prescribed for 81.42% of the patients and used at 
doses of 8 mg and 16 mg, of which 8 mg was most commonly prescribed in patients 
recommended with a single antiemetic treatment, while the utilization of 16 mg 
was applied in medications containing more than one antiemetic. Dexamethasone 
was endorsed in 44.28% of the patients with a range of 4mg - 20 mg. Among these, 
8 mg was the most normally utilized dose separately, as well as in combination with 
other agents. The other antiemetic, aprepitant represented 24.28% of the medica-
tions. Palonosetron was also recommended in this setting.
Aside from the antiemetics, other premedication utilized were Pantoprazole 
20 mg and 40 mg, Ranitidine 150 mg and Rabeprazole 20 mg. Of these 
Pantoprazole, 40 mg was the most commonly used, representing 72.85% of the 
total prescriptions.
6.5.2 Emetogenicity and antiemetics
The utilization of more up to date antiemetic agents has profoundly dimin-
ished the occurrence of nausea and vomiting in patients receiving chemotherapy, 
although these symptoms were not completely forestalled. All of the patients got an 
antiemetic medication preceding the chemotherapy.
A 5-HT3RA like Ondansetron, Palonosetron, and a steroid drug such as dexameth-
asone and Aprepitant were the normally endorsed premedication in our setting, either 
separately or in combination. The main high hazard associated emetogenic tranquilizer 
used in chemotherapy in our investigation was Cisplatin. The premedication gener-
ally recommended for this setting was Ondansetron 16 mg and Dexamethasone 8 mg 
either separately or in combination. Cyclophosphamide, Carboplatin, Doxorubicin, 
Epirubicin, Oxaliplatin, Cytarabine and Ifosfamide were the drugs used in cases of 
moderate emetogenicity. In this study, the premedication used by the patients were 
Ondansetron with 8 mg and 16 mg doses, Dexamethasone with 4 mg, 8 mg, 16 mg, 
and 20 mg doses, Palonosetron with 0.25 mg dose and Aprepitant with 125 mg dose.
6.6 Medication errors
In this project, the error percentage in the prescription as well as in the adminis-
tration of chemotherapy drugs in an oncology ward was also established.
6.6.1 Prescription error
The total error percentage reported in relation to the total number of prescrip-
tions (70) was of 24.28%.
17
Evaluation of the Medication Safety of Chemotherapy Drugs
DOI: http://dx.doi.org/10.5772/intechopen.96758
From these total error percentage 10% were due to drug–drug interaction, 2.8% 
to an unclear read, 2.8% of to lack of patient’s age,2.8% to poorly written medica-
tion order, 1.42% to lack of date, and 1.4% to a bad hand writing, making it difficult 
to read. A complete list of errors and their associated percentage is presented in 
Table 5.
6.6.2 Administration error
Drug administration is performed by nurses. The total error percentage reported 
in administration of chemotherapy drugs in all the 70 patients under study was of 
11.42%, out of which 2.85% were due to wrong administration dose, 2.85% to drug 
administration outside the guidelines, 1.42% to errors related to the speed in drug 
administration, and 1.45% to wrong administration technique. A complete error list 
is displayed in Table 6.
6.6.3 Prevention of medication errors
Currently, there are no sufficient strategies for estimating ME rates, and an 
assortment of self- reporting and non- self-reporting approaches should be utilized. 
The repeat of declared MEs, made the health care system to check carefully the 
Type of error Number of errors % of errors
Wrong drugs written on prescription 0 0
Dose of drug 0 0
Dosage of drug(inappropriate or wrong
dosage forms written on prescription)
0 0
Route of drug 0 0
Frequency 0 0
Date 1 1.42
Lack of patient’s gender 0 0
Lack of patient’s age 2 2.85
Ilegible (not clear enough to read) 2 2.85
Error in allergy documented 0 0
Error in location of treatment order 0 0
Nonstandard abbreviation used 0 0
Presence of therapeutic duplication, if any 0 0
Drug interaction if any 7 10
Food drug interaction if any 0 0
Signature of drug 0 0
Poorly written medication order 2 2.85
Miss interpreted handwritten ME 1 1.42
Fails to complete order 2 2.85
Total counts 17 24.2
8
Table 5. 
Types of medication error possible to occur in drug prescription.
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quality with which MEs are looked for, the procedure used, the patient populace, 
and the importance of errors.
We have concluded that a nurse is the perfect single individual to detect a ME. 
Firstly, by routinely surveying the suitability of the medication and differentiating 
the substituted drug to the doctor-composed request. Although, the nurse may be 
accused of assessing the whole procedure between request composing and appor-
tioning and afterwards, the association system.
Secondly, nurse ME declaration is the transcendent strategy in many, if 
not most restorative centers, give it ponder for understanding and improv-
ing the medical caretaker, revealing procedure of progressively summed up 
application.
Thirdly, although disliking, everyone should clearly promote a ME presenta-
tion/reduction. The ME aversion is an essential activity and a fundamental piece 
of significant worth in nursing. As O’Shea has noted, a nurse is accountable and 
responsible for the drug administration and ME anticipation is currently considered 
as a national nursing basic. [20]
Taking into account the jobs of drug specialists and nurses in MAE reveal-
ing cover, the benefit of including the drug store, at any foundation, would be 
conversely related to the adequacy of nurse reporting. Considering our decreased 




Wrong drugs administration by nurses 0 0
Wrong dosage administration for a
recommended drugs by nurses
0 0
Failure to give a drug by the health care supplier 1 1.42
Wrong dose administration 2 2.85
Wrong administration technique 1 1.42
Drug administration to the wrong patient 0 0
Medication discontinuation failure 0 0
Omission (failure to administer an ordered dose before the next scheduled 
dose)
1 1.42
Double dosing by nurses 0 0
Use of incorrect (wrong)drug vehicle 0 0
Drug administration after a discontinuation order 0 0
Administration of incompatible medication 0 0
Drug administration without a physician order 0 0
Drug administration outside the established guidelines 2 2.85
Administration of an expired drug 0 0
Error in the speed of drug administration 1 1.42
Food-drug interaction 0 0
Total Counts 8 11.42
Table 6. 
Types of medication errors possible to occur in drug administration.
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rate of reporting late organizations, our MAE rates are presumably similar to those 
detailed from different programs with compelling interception systems in place. 
In total, the prescribed current benchmarks displayed error rates of about 5% 
for association plus intercepted MEs, and roughly 0.1% to 0.2% for MAEs. These 
numbers appear to be commonly autonomous of patient age and chemotherapy 
versus non-chemotherapy solutions. For organization plus captured MEs, type 1 
errors have been commonly typical. [a type I error is when a researcher rejects the 
null hypothesis that is actually true in reality. In other words, a type I error is a false 
positive or the conclusion that a treatment does have an effect, when in reality it 
does not have].
Our investigation shows that the MAE may fundamentally move toward nurse 
dispensing and organization. Our outcomes propose that in order to improve the 
formulation of MAE prevention strategies, each therapeutic center should initially 
be aware of where in the process of mentioning, apportioning, and overseeing 
medicines, the overwhelming number of MAEs starts.
6.7 Adverse effects
The overall AEs observed in both genders were practically identical. 
Nevertheless, the effects on gastro intestinal tract and musculoskeletal system were 
higher in females, which may be explained by a higher affectability of this gender 
by these particular effects. Iron deficiency is seen as a moderately basic condition 
in patients with disease, particularly those with solid tumors, lymphomas and 
receiving myeloid suppressive chemotherapy. Treatment for chemotherapy-induced 
anemia (CIA) started when the hemoglobin level fell beneath 12 mg/dl with oral or 
intravenous iron enhancements. Blood transfusions were picked in serious cases. 
In our setting, the specialists generally recommended ferrous sulfate, folic acid 
and Vitamin B12 prophylactic estimates, for example, great oral hygiene, avoid-
ance of spicy food, and utilization of mild-flavored toothpaste and saline peroxide 
mouthwashes 3 or 4 times per day, ingrained where appropriate for limiting oral 
mucositis.
7. Conclusions
The AEs related with the utilization of anticancer drugs were assessed during 
half a year. The AE prevalence encountered and experienced suggests that all 
patients getting cytotoxic medication may endure at any rate one AE. Nausea, 
vomiting, decline appetite, alopecia, anemia, nail discoloration and anorexia 
were the most prevalent AEs detected. Correlation of the AEs observed with the 
group of individuals to achieve larger purpose did not show some new AEs. The 
frequency of AEs has shown to be extensively high and arouse from the utiliza-
tion of existing premedication. Given the disclosures of the examination, the 
attempts to confine the AEs related with the anticancer medicines ought to be 
centered around. Expanding the mindfulness through informative intercession, 
actualize proper usage of premedication and non- pharmacological treatment are 
essential for improved personal satisfaction. Treatment rules are noteworthy in 
light of the fact that they outfit clinicians with a movement of proposition made 
from the international expert’s dependent on their elucidation of the latest clinical 
trial data. In spite of certain qualifications among the MASCC, ASCO, and NCCN 
rules, all gave invigorated references and proposals to direct the perfect use of 
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antiemetics. Nevertheless, the necessity for a progressively and reasonable usage 
of treatment rules is critical to improve the nature of thoughts of cancer patients. 
Significant detailed MAE rates on our hospital ward (0.04% of medication 
organizations and 0.03 MAEs/patient admission.) have all the earmarks of being 
generally low due to the use of current security rules. An accentuation on contem-
plating MAEs at individual foundations is probably going to result in significant 
technique changes, improved effectiveness of MAE revealing, and various other 
advantages.
8. Limitation
The major limitation of the study was the inability to distinguish between imme-
diate and delayed AEs due to the difficulty of the patients in recall the AE’s.
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